Floatz logo

Pelabresib

Myelodysplastic/Myeloproliferative Neoplasm

Constellation PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
Evomela
M.D. Anderson Cancer Center
Phase 2/3BBB
Busulphan
Jacqueline Garcia, MD
Phase 2/3BBB
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Pelabresib is also rated in:

cancerDormant
BB
Indicative ·
64 / 100
View asset →
neoplasmDormant
B
Indicative ·
58 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →